2020
DOI: 10.1038/s41390-020-0993-4
|View full text |Cite
|
Sign up to set email alerts
|

Pulmonary hypertension in bronchopulmonary dysplasia

Abstract: Bronchopulmonary dysplasia (BPD) is a major complication in prematurely born infants. Pulmonary hypertension (PH) associated with BPD (BPD-PH) is characterized by alveolar diffusion impairment, abnormal vascular remodeling, and rarefication of pulmonary vessels (vascular growth arrest), which lead to increased pulmonary vascular resistance and right heart failure. About 25% of infants with moderate to severe BPD develop BPD-PH that is associated with high morbidity and mortality. The recent evolution of broade… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
103
0
12

Year Published

2020
2020
2023
2023

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 113 publications
(116 citation statements)
references
References 78 publications
(128 reference statements)
1
103
0
12
Order By: Relevance
“…Approximately one-fourth of infants with moderate to severe BPD developed pulmonary hypertension later in their life (30). In our cohort, 22 infants developed moderate to severe BPD (13 in group A, nine in group B).…”
Section: Limitationsmentioning
confidence: 71%
“…Approximately one-fourth of infants with moderate to severe BPD developed pulmonary hypertension later in their life (30). In our cohort, 22 infants developed moderate to severe BPD (13 in group A, nine in group B).…”
Section: Limitationsmentioning
confidence: 71%
“…Through murine studies PFKFB3 has been identified as potential therapeutic target for the treatment of Pulmonary Hypertension (PH) (53). Increased expression PFKFB3 in BPD is consistent with PH associated with BPD which is characterized by abnormal vascular remodeling, and vascular growth arrest, which are well documented pathophysiology associated with BPD (54). In vitro studies have reported that PFKFB3-kinase activity attenuates the activation of T cells, and demonstrated the effectiveness of PFKFB3 antagonists, even in small amounts, as T cell immunosuppressive agents (55).…”
Section: Discussionmentioning
confidence: 93%
“…Among the differentially expressed genes associated with BPD, PFKFB3 gene was not only consistently identified as differentially expressed in BPD subjects irrespective of the approach used, but was also identified as a BPD marker in an independent transcriptomic analysis of PBMCs derived from BPD subjects (9). Through murine studies PFKFB3 has been identified as potential therapeutic target for the treatment of Pulmonary Hypertension (PH) (36) Increased expression PFKFB3 in BPD is consistent with PH associated with BPD which is characterized by abnormal vascular remodeling, and vascular growth arrest, which are well documented pathophysiology associated with BPD (37). One of the differentially expressed genes, KLF9 , has been previously identified as differentially expressed in T cells from patients with autoimmune rheumatoid arthritis (38), while another, DLG5, is involved in the HIPPO pathway.…”
Section: Discussionmentioning
confidence: 99%